Sign inJoin waitlistJoin the waitlist

BW

Brenda Wittman

Physician · Providence Alaska Medical Center

Credentials: · · ·

History

Providence Alaska Medical Center
2019–Present

Pediatric Hematology/Oncology
University of Rochester Medicine
2002–2005
Pediatrics
1999–2002
Doctor of Medicine
1995–1999

Research

Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials
Systematic review or meta-analysis · Cancer Treatment Reviews · 2006 · First of 3 authors · 39 citations
Late effects in adult survivors of pediatric cancer: a guide for the primary care physician
Review · The American Journal of Medicine · 2012 · 37 citations
A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate
Case report · Leukemia Research · 2004 · First of 9 authors · 16 citations

John Horan
2 papers
Emmanuel Katsanis
1 paper
Gary Lyman
1 paper
Joe Rutledge
1 paper
John Bennett
1 paper
LK
Lisa Kopp
1 paper
LM
Luci MacNeal
1 paper · 1 as a resident
Luz Pelayo-Katsanis
1 paper
MX
Min Xu
1 paper
PW
Puja Whitlow
1 paper
RF
Raymond Felgar
1 paper

Clinical trials

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Site PI · Recruiting · Phase 1, Phase 2
PedAL BCU, LLC
2022–2030
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Site PI · Recruiting · Phase 3
Children's Oncology Group
2022–2031